<DOC>
	<DOCNO>NCT02325349</DOCNO>
	<brief_summary>The primary objective Phase II study evaluate use label RGD ligand PET/CT predict and/or early ass efficacy chemotherapy include agent antiangiogenic effect . The predictive value approach determine independent assessor basis data end treatment : RECIST 1.1 criterion CT MRI , PERCIST criterion FDG PET/CT , clinical , endoscopic histological finding .</brief_summary>
	<brief_title>PET/CT Imaging Angiogenesis Lung Head Neck Cancers Prior During Chemotherapy With Antiangiogenic Agents</brief_title>
	<detailed_description>Prospective , multicentre , open label , phase II clinical trial diagnostic radiopharmaceutical efficacy tolerability 18F 68Ga label RGD peptide detection malignant tissue express integrins , predict therapeutic response lesion advance head neck cancer advance non-small cell lung cancer treatment include agent antiangiogenic effect .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<mesh_term>Radiopharmaceuticals</mesh_term>
	<criteria>1A . Male female &gt; 18year old nonsmall cell lung carcinoma ( NSCLC ) meeting follow criterion : advanced NSCLC proven histology cytology , treatment include agent antiangiogenic effect schedule Measurable lesion &gt; 1 cm short axis . Pretherapeutic contrastenhanced CT thorax upper abdomen available mask read appropriate medium FDG PET/CT available mask read appropriate medium 1B . Male female &gt; 18year old head neck ( H &amp; N ) cancer meeting follow criterion : advanced H &amp; N cancer proven histology cytology , treatment include agent antiangiogenic effect schedule Measurable lesion &gt; 1 cm short axis . Pretherapeutic native contrast enhance CT MRI head neck available mask read appropriate medium FDG PET/CT available mask read appropriate medium Otorhinolaryngologic ( ORL ) examination include ORL fibroscopy and/or optionally panendoscopy . 2 . Capacity remain without movement PET/CT examination 3 . ECOG performance status ≤ 2 inclusion 4 . Patient life expectancy ≥ 24 week inclusion . 5 . In fertile female , inclusion pregnancy must rule 6 . Volunteer capable follow necessary instruction trial 7 . Informed consent sign patient 8 . Affiliation social security system 1 . In patient lung cancer : lung cancer predominance smallcell pure bronchioloalveolar cancer . 2 . Scheduled treatment include antiangiogenic agent 3 . Patient´s physical condition permit participation clinical trial accord opinion investigator responsible centre 4 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Angiogenesis</keyword>
	<keyword>Integrins</keyword>
	<keyword>RGD PET/CT</keyword>
	<keyword>FDG PET/CT</keyword>
	<keyword>Predictive value</keyword>
	<keyword>Therapeutic response</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Tolerability</keyword>
</DOC>